TH

Thalassa Holdings Ltd.

A holding company active in property rentals and marine seismic & defense R&D.

THAL | IL

Overview

Corporate Details

ISIN(s):
VGG878801114
LEI:
2138002739WFQPLBEQ42
Country:
Virgin Islands (British)
Address:
FOLIO CHAMBERS, VG1110 ROAD TOWN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Thalassa Holdings Ltd. is a holding company engaged in international business activities. The company's operations are primarily focused on two segments: Rental Income, derived from its property interests, and Product Development. The Product Development segment concentrates on marine seismic and defense research and development, including geophysical project management, related services, and the supply of equipment. The company's strategic goal is to generate long-term shareholder value by deploying capital and expertise into investment opportunities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-29 11:39
M&A Activity
Thalassa Holdings Ltd: Trading Update
English 9.9 KB
2025-10-29 11:39
M&A Activity
Thalassa Holdings Ltd: Trading Update
English 11.4 KB
2025-10-15 09:35
Board/Management Information
Thalassa Holdings Ltd: Thalassa Board reaches agreement with Newmark Security p…
English 9.1 KB
2025-10-15 09:35
Board/Management Information
Thalassa Holdings Ltd: Thalassa Board reaches agreement with Newmark Security p…
English 10.5 KB
2025-10-08 08:30
Regulatory News Service
Thalassa Holdings Ltd: Letter to Newmark Security plc (NWT) Shareholders
English 562.7 KB
2025-10-08 08:30
Major Shareholding Notification
Thalassa Holdings Ltd: Letter to Newmark Security plc (NWT) Shareholders
English 722.8 KB
2025-09-29 10:57
Board/Management Information
Thalassa Holdings Ltd: Surgical Innovations Group plc
English 7.9 KB
2025-09-29 08:30
Interim Report
Thalassa Holdings Ltd: 2025 Interim Results
English 408.7 KB
2025-09-29 08:30
Earnings Release
Thalassa Holdings Ltd: 2025 Interim Results
English 496.5 KB

Automate Your Workflow. Get a real-time feed of all Thalassa Holdings Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Thalassa Holdings Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Thalassa Holdings Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.